B. Jaynthi, P. Parameshwar, Tajuddin Baba M.D., Kishore Pratap Patil, G. Cheranjeevi
B. Jaynthi1, P. Parameshwar2, Tajuddin Baba M.D.1, Kishore Pratap Patil1, G. Cheranjeevi3
1Annamalai University, Annamalai Nagar, Chidhambaram, Tamil Nadu, India
2Joythismathi Institute of Pharmaceutical Sciences, Timmapur, Karimnagar, A.P-505481
3Pulipati Prasad Institute of Pharmaceutical Sciences, Kammam
Volume - 5,
Issue - 5,
Year - 2012
Rosiglitazone is an oral drug that reduces the amount of sugar (glucose) in the blood. It is used for treating patients with type-2 diabetes and is in a class of anti-diabetic drugs called thiazolidinediones. Our diabetes clinic treatment algorithm mandates starting small doses of either a sulfonylurea agent or Metformin and increasing the dose every two weeks until either a fasting plasma glucose (FPG) concentration of <130 mg/dl is attained or a maximal (tolerated in the case of Metformin) dose is reached. The efficacy of thiazolidinediones, as compared with other oral glucose-lowering medications, in maintaining long-term glycemic control in type-2 diabetes is not known. We evaluated Rosiglitazone and metformin as initial treatment for type-2 diabetes mice. The potential risks and benefits, the profile of adverse events and the costs of these two drugs should all be considered to help inform the choice of pharmacotherapy for patients with type-2 diabetes. Rosiglitazone and Metformin are two pharmacologic agents useful in conditions characterized by insulin resistance. The aim of our study was to compare the efficacy of Rosiglitazone versus Metformin. Only the rosiglitazone group showed a significant reduction in insulin levels. Metformin and Rosiglitazone were well-tolerated.
Cite this article:
B. Jaynthi, P. Parameshwar, Tajuddin Baba M.D., Kishore Pratap Patil, G. Cheranjeevi. Effect of insulin sensitizer, rosiglitazone in streptozotocine induced diabetic db/db mice model. Research J. Pharm. and Tech. 5(5): May2012; Page 619-623.
B. Jaynthi, P. Parameshwar, Tajuddin Baba M.D., Kishore Pratap Patil, G. Cheranjeevi. Effect of insulin sensitizer, rosiglitazone in streptozotocine induced diabetic db/db mice model. Research J. Pharm. and Tech. 5(5): May2012; Page 619-623. Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2012-5-5-19